

Fig. S2: Immunophenotypic characterizaton of *Eed$^{Δ/Δ}$/Cdkn2a^{ko} MLL-AF9* leukemia. *Eed* inactivation does not lead to aberrant expression of B-lineage markers B220/CD19 (a) or T-lineage markers CD4/CD8 (b) in vivo. c) Preleukemic *Eed$^{Δ/Δ}$/Cdkn2a^{ko}MLL-AF9* clones grown ex vivo show relatively low expression of Gr-1 compared to d) *Eed^{ff}/Cdkn2a^{ko} MLL-AF9* clones. e) *Eed^{ff}/Cdkn2a^{ko} MLL-AF9* clones have a similar proportion of Gr-1/Mac-1 double positive cells in vitro and in vivo, whereas *Eed$^{Δ/Δ}$/Cdkn2a^{ko}MLL-AF9* clones evolve during in vivo leukemogenesis to co-express Gr-1 and Mac1 on a higgher proportion of cells. See also c)-d) and Figure 2. f) *Eed^{ff}/Cdkn2a^{ko}MLL-AF9* clones have a similar proportion of Kit-positive cells in vitro and in vivo, whereas *Eed^{ΔΔ}/Cdkn2a^{ko} MLL-AF9* clones evolve in vivo to express a higher proportion of Kit-positive cells.